Vertex Pharmaceuticals presents ALYFTREK data: BofA targets Vertex Pharmaceuticals stock at USD 667

Published on 10/19/2026 at 10:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ALYFTREK data dated October 17 put fair value at USD 571.39. Vertex Pharmaceuticals stock trades at EUR 447.95 on October 19, 2026 at Lang & Schwarz.

Pipeline data and valuation

ALYFTREK data on October 17, 2026 supported a fair value of USD 571.39.
BofA cut its Vertex target from USD 672 to USD 667 on October 12, 2026.
Vertex Pharmaceuticals stock trades at EUR 447.95 at 10:07 a.m. CEST at Lang & Schwarz on October 19, 2026.

Isometrische 3D-Grafik der Pharma-Wertschöpfungskette von Labor bis Auslieferung — Vertex Pharma US92532F1003 illustriert die isometrische Wertschöpfungskette der Branche von Forschung bis zur Distribution, Illustration mit AI erstellt.

Vertex Pharmaceuticals (ISIN US92532F1003) was trading at EUR 447.95 at Lang & Schwarz on October 19, 2026 at 10:07 a.m. CEST. Yahoo Finance reported on October 17 that new ALYFTREK data pointed to a fair value of USD 571.39, while Investing.com said BofA cut its target from USD 672 to USD 667 on October 12.

Pipeline data meet valuation

The ALYFTREK update adds a development angle ahead of Vertex's next results. The fair-value estimate of USD 571.39 is a valuation reference, not a company-issued forecast, and the report linked the figure to interim data involving pancreatic function in young children.

Investing.com said BofA modeled third-quarter Trikafta revenue at USD 2.42 billion against consensus of USD 2.54 billion. The comparison puts near-term execution beside the longer pipeline narrative, with cystic fibrosis still central to the model.

What does the target imply?

BofA's revised USD 667 target remained a Buy-rated view after the USD 5 reduction. MarketBeat reported on October 17 that Wall Street Zen upgraded Vertex from Hold to Buy, while its survey showed 24 Buy, one Strong Buy and three Hold ratings. Those figures describe external opinions, not a recommendation from this article.

Three events frame the stock

The recent chronology starts with second-quarter revenue of USD 3.33 billion on August 3, 2026, up 12.5 percent year over year, as reported by MarketBeat. BofA cut its target to USD 667 from USD 672 on October 12, 2026, according to Investing.com. On October 17, 2026, ALYFTREK data supported the USD 571.39 fair-value estimate reported by Yahoo Finance.

Dates for the next catalyst

Business Wire reported on October 7 that Vertex will publish third-quarter 2026 results on November 2, 2026, after the market close. The company scheduled its earnings call for 4:30 p.m. ET on the same date.

Stock price and investor context

The main near-term test is whether the November report supports the USD 13.1 billion to USD 13.2 billion full-year revenue guidance cited by Investing.com. Vertex Pharmaceuticals was trading at EUR 447.95 at Lang & Schwarz on October 19, 2026 at 10:07 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharmaceuticals stock.